Table 3.

Consensus recommendations on clinical mpMRI reports

Recommendations on clinical mpMRI reports
The image quality of the mpMRI be reported. mpMRI should be scored to rule out Gleason score 7 (including 3 + prominent 4), and/or volume ≥0.5 mL, and/or extraprostatic extension/seminal vesicle invasion. The mpMRI scoring system recommended is the ‘Likert‐assessment’ system (both for lesion‐scoring and whole‐gland scoring). Equivocal prostate mpMRI (Likert‐impression 3) should be double‐read if avoiding biopsy is under consideration. Discordant mpMRI scores with biopsy results should be retrospectively double‐read.
The following should be scored on a 1–5 scale for likelihood of involvement: ᴑExtraprostatic extension. ᴑSeminal vesicle involvement. ᴑBladder neck involvement. ᴑNeurovascular bundle involvement. ᴑRectal wall involvement. ᴑBladder wall involvement. ᴑPeripheral zone (PZ) and Transition zone (TZ) tumour should be measured from any sequence on which it is best seen.
The following quantitative metrics should be included within an mpMRI report: ᴑProstate gland volume and tumour size should be measured on T2‐weighted imaging using 3‐diameters × 0.52 (prolate ellipse formula). ᴑTo ensure consistency, tumour should be measured as 3‐diameters or volume estimation by the product of 3 diameters × 0.52. ᴑFor software‐targeted biopsy purposes, tumour should be contoured on the sequence required by targeted biopsy fusion software. ᴑFor targeted biopsy purposes, in a lesion >1 cm, the most suspicious area/spot for significant tumour, (i.e. the ‘hot‐spot’) should be additionally indicated (e.g. by contouring, via arrow‐heads, etc.).